Showing 1–16 of 16 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Isaquel Silva, Sebastian Nielsen, Peter Aaby, Christine Stabell Benn, Frederik Schaltz-Buchholzer
**BACKGROUND:** Within a randomised controlled trial providing Bacillus Calmette-Guérin, measles vaccine, or placebo to women of fertile age, we aimed to study the risk of adverse events following vaccination. This study addresses the lack of data on adverse reactions in adu…
Angelique Kany Kany Luabeya, Virginie Rozot, Claire Imbratta, Frances Ratangee, Justin Shenje, et al.
**BACKGROUND:** An effective adult vaccine is needed to control tuberculosis. We evaluated the safety and immunogenicity of a live-attenuated Mycobacterium tuberculosis vaccine (MTBVAC). **METHODS:** This single-centre, phase 1b-2a, double-blind, dose-escalation, randomised cont…
Álvaro H Borges, Marisa Russell, Dereck Tait, Thomas J Scriba, Elisa Nemes, et al.
**BACKGROUND:** People with tuberculosis who complete treatment remain at risk of recurrent disease. The vaccine H56:IC31 has been shown to be safe and immunogenic in phase 1 and 2 studies, but whether it can reduce the risk of tuberculosis recurrence is unknown. **METHODS:** In…
Bethou Adhisivam, Chinnathambi Kamalarathnam, B Vishnu Bhat, Kumutha Jayaraman, Siva P Namachivayam, et al.
**OBJECTIVE:** To test the effect on all cause neonatal mortality (aged ≤28 days) of a dose of BCG Danish vaccine and oral polio vaccine (OPV) administered to newborn babies weighing <2000 g. **DESIGN:** Multicentre, open label, randomised controlled trial SETTING: Three …
Julie Odgaard Vedel, Oides Furtado, Laerte Lima Almeida, Jailson Sydenei Dias Martins, Sanne Møller Thysen, et al.
**BACKGROUND:** A correct vaccination technique is important for developing BCG scars. Having a BCG scar is associated with lower mortality among BCG-vaccinated children. **AIM:** To compare BCG-scar prevalences among children vaccinated before and after refresher training in BC…
Nicole L Messina, Laure F Pittet, Emily K Forbes, Kate L Francis, Kaya Gardiner, et al.
**BACKGROUND:** Respiratory tract infections (RTI) are among the leading causes of hospitalisation and death for children under 5 years. We aimed to determine if neonatal BCG vaccination reduces early life hospitalisations for lower RTI (LRTI) in a low-tuberculosis endemic s…
Laure F Pittet, Dan Casalaz, Susan Donath, Kaya Gardiner, Casey Goodall, et al.
**BACKGROUND:** Bacille Calmette-Guérin (BCG) vaccine, primarily used against tuberculosis, has off-target (non-specific) immunomodulatory effects, including potential protection against recurrences of latent herpes simplex virus (HSV) infections. Recurrent episodes of HSV h…
Alemnew F Dagnew, Linda L Han, Kogieleum Naidoo, Lee Fairlie, James C Innes, et al.
**BACKGROUND:** M72/AS01is a recombinant fusion protein vaccine candidate derived from two Mycobacterium tuberculosis antigens (Mtb32A and Mtb39A) and AS01adjuvant. We evaluated safety and immunogenicity of M72/AS01in people living with HIV in South Africa. **METHODS:** In this …
Ramon Andrade de Souza, Florisneide Rodrigues Barreto, Carla Cristina Oliveira de Jesus Lima, Marcio Santos da Natividade, Carlos Antônio de Souza Teles Santos, et al.
**BACKGROUND:** Can vaccination with Bacille Calmette-Guérin prevent clinical progression of COVID-19? Data from the BCG-REVAC trial was archived in a database, creating an excellent opportunity to link it to notified cases of COVID-19 to evaluate the efficacy of BCG against…
Oscar Buisan, Pol Servian, Sonia Pedreño-Lopez, Joan Pagès, Victor Urrea, et al.
Intravesical bacillus Calmette-Guérin (BCG) is the standard treatment for high-risk non-muscle-invasive bladder cancer (NMIBC); however, recurrence and progression remain major challenges. To explore a heterologous prime-boost strategy, we conducted the RUTIVAC-1 trial (NCT0…
Alexander C Schmidt, Lee Fairlie, Elizabeth Hellström, Angelique Luabeya Kany Kany, Keren Middelkoop, et al.
**BACKGROUND:** In a previous phase 2 trial, bacille Calmette-Guérin (BCG) revaccination was not shown to provide protection from primaryinfection but prevented sustainedinfection, defined by an initial conversion on a QuantiFERON-TB (QFT) test (an interferon-release assay) …
Manjula Singh, Sindhu Joshi, Vikram Vohra, Rohit Sarin, Suchit Vasant Kamble, et al.
… in participants with tuberculin skin test positivity. Both vaccines were well tolerated with mild local reactions in about a third of participants. VPM1002 and Immuvac inducedspecific polyfunctional CD4+ T cells. Post hoc analyses showed vaccine efficacy of 64.6% (95% CI 16.3% t…
Ahmed Mohamed Dirie, Nor Afiah Mohd Zulkefli, Salmiah Md Said, Ahmed Zaid Fatah Azman, Kassim Abdi Jimale, et al.
**BACKGROUND:** Tuberculosis (TB) in children is one of the most significant public health crises in Somalia. This issue is aggravated by the fact that only 36.7% of children aged 12 to 23 months receive the Bacillus Calmette-Guérin (BCG) vaccine in Somalia, which helps prev…
Julia L Marshall, Iman Satti, Mirvat Surakhy, Stephanie A Harris, Hazel Morrison, et al.
The development of an effective vaccine against Mycobacterium tuberculosis is hampered by an incomplete understanding of immunoprotective mechanisms. We utilise an aerosol human challenge model using attenuated Mycobacterium bovis BCG, in BCG-naïve UK adults. The p…
Luciana Saboya, Keini Buosi, Tiago Silva, Elaine Candido, Josiane Morari, et al.
**OBJECTIVE:** To determine the safety and the role of modulating cytokines and proteases in the immune response to intravesical Bacillus Calmette-Guérin (BCG) when primed with systemic intradermal BCG. **METHODS:** Phase 1 and mechanistic longitudinal, prospective, single-…
Xichao Ou, Guan Liu, Baozhen Peng, Yuehua Li, Hegui Yan, et al.
**BACKGROUND:** Accurate and cost-effective screening for Mycobacterium tuberculosis (Mtb) infection remains a global challenge. While Interferon-γ Release Assays (IGRAs) offer high specificity, their widespread deployment is hindered by high costs and technical complexity.…